Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Down 66.1% in December

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 6,679 shares, a decrease of 66.1% from the November 30th total of 19,690 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average trading volume of 34,557 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 34,557 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.3% of the shares of the stock are sold short.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Sachetta LLC grew its stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 15,259 shares of the company’s stock after buying an additional 4,593 shares during the quarter. Sachetta LLC owned approximately 0.99% of Xenetic Biosciences worth $60,000 as of its most recent SEC filing. Institutional investors own 15.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Xenetic Biosciences currently has an average rating of “Reduce”.

Xenetic Biosciences Stock Performance

Xenetic Biosciences stock opened at $2.08 on Friday. Xenetic Biosciences has a 52 week low of $1.90 and a 52 week high of $13.93. The stock has a market capitalization of $4.77 million, a P/E ratio of -1.01 and a beta of 2.40. The stock has a fifty day moving average of $2.71 and a 200-day moving average of $3.23.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Wednesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.16. The firm had revenue of $1.03 million for the quarter. Xenetic Biosciences had a negative return on equity of 64.66% and a negative net margin of 110.42%. On average, research analysts forecast that Xenetic Biosciences will post -1.01 earnings per share for the current year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.